Integral Molecular: Selected Partner
Since 2001, Integral Molecular has specialized in developing and applying innovative technologies that advance therapeutic discovery against difficult membrane protein targets. Their industry-leading biotherapeutic specificity testing platform, the Membrane Proteome Array™ (MPA), has been used by hundreds of companies worldwide to de-risk thousands of targeted therapeutics. The MPA enables data-driven decisions during lead selection and development, and the FDA routinely accepts its data in IND filings.
Our partnership with Integral Molecular provides a seamless transition to MPA services after antibody production, ensuring your therapeutics meet the highest standards for target specificity.
Key facts
- Specialization: Specificity testing for targeted therapeutics
- Technology: Membrane Proteome Array™ screening ~6,000 native membrane proteins, Secreted Proteome Library screening ~1,200 secreted proteins
- Services: Specificity testing, target identification, IND-ready data package
- Website: https://www.integralmolecular.com/membrane-proteome-array/
Location
Headquarters
One uCity Square
25 N 38th Street, Suite 800
Philadelphia, PA 19104
About Integral Molecular
Integral Molecular operates a research center in Philadelphia, PA, equipped with state-of-the-art molecular and cell biology facilities, robotics, and high-throughput instrumentation. Their team brings deep expertise in structural biology, biochemistry, and virology, with one-third of their scientific staff holding PhDs. Integral Molecular’s technologies have been published in over 500 papers and patents, including articles in Cell, Science, and Nature.
Unlock the full potential of your research with Integral Molecular and evitria
Through our strategic partnership with Integral Molecular, evitria offers a seamless handoff to the industry’s leading biotherapeutic specificity testing platform, the Membrane Proteome Array ™ (MPA). By integrating MPA testing directly into your development workflow, you can confidently identify and advance only the most specific therapeutic candidates, generating FDA-accepted data that strengthens IND submissions and reduces preclinical risk.
